Nature Communications (Feb 2024)

CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver

  • Alexander J. Hu,
  • Wei Li,
  • Calvin Dinh,
  • Yongzhao Zhang,
  • Jamie K. Hu,
  • Stefano G. Daniele,
  • Xiaoli Hou,
  • Zixuan Yang,
  • John M. Asara,
  • Guo-fu Hu,
  • Stephen R. Farmer,
  • Miaofen G. Hu

DOI
https://doi.org/10.1038/s41467-024-45294-z
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Increased de novo lipogenesis (DNL) in white adipose tissue is associated with insulin sensitivity. Under both Normal-Chow-Diet and High-Fat-Diet, mice expressing a kinase inactive Cyclin-dependent kinase 6 (Cdk6) allele (K43M) display an increase in DNL in visceral white adipose tissues (VAT) as compared to wild type mice (WT), accompanied by markedly increased lipogenic transcriptional factor Carbohydrate-responsive element-binding proteins (CHREBP) and lipogenic enzymes in VAT but not in the liver. Treatment of WT mice under HFD with a CDK6 inhibitor recapitulates the phenotypes observed in K43M mice. Mechanistically, CDK6 phosphorylates AMP-activated protein kinase, leading to phosphorylation and inactivation of acetyl-CoA carboxylase, a key enzyme in DNL. CDK6 also phosphorylates CHREBP thus preventing its entry into the nucleus. Ablation of runt related transcription factor 1 in K43M mature adipocytes reverses most of the phenotypes observed in K43M mice. These results demonstrate a role of CDK6 in DNL and a strategy to alleviate metabolic syndromes.